A marketing analysis of the pharmaceutical market for drugs - derivatives of 9,10-anthraquinone was carried out. It is shown that in the Ukrainian market, the vast majority of the assortment of these drugs is formed by foreign-made drugs, the leaders of which are the manufacturing countries Austria, Italy, Germany and India. It has been determi ned that the majority of anthraquinone drugs are represented by agents for the treatment of diseases of various types of cancer and strengthening of the intestinal reticulum. It has been established that «Sinbias Pharma» LLC is engaged in the production of four anticancer substances in Ukraine. For preparations based on anthraquinone-containing medicinal herbal raw materials, domestic manufacturers are PJSC «Liktravy» and PJSC Pharmaceutical Factory «Viola», and the producers of senna glycosides are JSC «Lubnypharm», «Ternopharm» LLC and Pharmaceutical company «Zdorovye». Injection solutions, lyophilisates, tablets and hard capsules are the main dosage forms of drugs - derivatives of 9,10-anthraquinone
1. Fouillaud, M., Venkatachalam, M., Girard-Valenciennes, E., Caro, Y., Dufossé, L. (2016). Anthraquinones and derivatives from marine-derived fungi: Structural Diversity and Selected Biological Activities. Marine Drugs, 14(4), 64. doi:10.3390/md14040064. Retrieved from https://www.mdpi.com/1660-3397/14/4/64
https://doi.org/10.3390/md14040064
2. Fouillaud, M., Caro, Y., Venkatachalam, M., Grondin, I., & Dufossé L. (2018). Anthraquinones. In: L. M. L. Nollet; J. A. Gutiérrez-Uribe (eds). Phenolic Compounds in Food Characterization and Analysis, 130-170. CRC Press.
https://doi.org/10.1201/9781315120157-9
3. Malik, E. M. & Müller, C. E. (2016). Anthraquinones As Pharmacological Tools and Drugs. Medicinal Research Reviews, 36, 705-748. doi:10.1002/ med.21391
https://doi.org/10.1002/med.21391
4. Hussain, H., Al-Harrasi, A., Al-Rawahi, A., Green, I. R., Csuk, R., Ahmed, I., Shah, A., Abbas, G., Rehman, N. U. & Ullah, R. (2015). A fruitful decade from 2005 to 2014 for anthraquinone patents, Expert Opinion on Therapeutic Patents, 25(9), 1053-1064. doi:10.1517/ 13543776.2015.1050793
https://doi.org/10.1517/13543776.2015.1050793
5. Tikhomirov, A. S., Shtil, A. A., Shchekotikhin, A. E. (2018). Advances in the Discovery of Anthraquinone-Based Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 159-183. doi:10.2174/1574892 813666171206123114.
https://doi.org/10.2174/1574892813666171206123114
6. Siddamurthi, S., Gutti, G., Jana, S., Kumar, A., & Singh S. K. (2020). Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Medicinal Chemistry, 12(11), 1037-1069. doi:10.4155/fmc-2019-0198.
7. Zvarich, V. I., Stasevich, M. V.; Stan'ko, O. V.; Komarovskaya-Porokhnyavets, E. Z.; Poroikov, V. V.; Rudik, A. V.; Lagunin, A. A.; Vovk, M. V.; & Novikov, V. P. (2014). Computerized prediction, synthesis, and antimicrobial activity of new amino-acid derivatives of 2-chloro-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide. Pharmaceutical Chemistry Journal, 48, 584-588. doi: 10.1007/s11094-014-1154-z.
https://doi.org/10.1007/s11094-014-1154-z
8. Zvarych, V., Stasevych, M., Novikov, V., & Vovk, M. (2021). Synthesis and Study of Antimicrobial Activity of 2-Dithiocarbamate-N-(9,10-Dioxo-9,10-Dihydroanthraceny l)Acetamides, Biointerface Research in Applied Chemistry, 11(1), 7725-7734. doi: 10.33263/ BRIAC111.77257734
https://doi.org/10.33263/BRIAC111.77257734
9. Zvarych, V., Stasevych, M., Novikov, V., Rusanov, E., Vovk, M., Szweda, P., Grecka, K., & Milewski, S. (2019). Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a new class of antistaphylococcal agents: synthesis and biological evaluation. Molecules, 24, 4581. doi:10.3390/ molecules24244581. Retrieved from https://www.mdpi. com/1420-3049/24/24/4581
https://doi.org/10.3390/molecules24244581
10. Halenova, T. I., Nikolaeva, I. V., Stasevych, M. V., Zvarych, V. I., Lunin, V. V., Novikov, V. P., & Savchuk, O. M. (2017). Platelet aggregation under the influence of some dithiocarbamate derivatives of 9,10-anthracenedione. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8, 1626-1632. Retrieved from https://www.rjpbcs.com/ pdf/2017_8(1)/[203].pdf
11. Stasevych, M. V., Zvarych, V. I., Spreis, D. R., & Yaremkevych, O. S. (2019). Computer prediction and verification of antioxidative activity of exo-functionalized derivatives of 9,10-antraquinone. Chemistry, Technology and Application of Substances, 2(1), 83-91. doi:10.23939/ ctas2019.01.083
https://doi.org/10.23939/ctas2019.01.083
12. Thomson Reuters Integrity database. Retrieved from http:// https://integrity.clarivate.com/integrity/xmlxsl/ (accessed December 14, 2019)
13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy, (2020). Retrieved from http://www.drlz.com.ua (in Ukrainian)
14. A searchable version of the complete ATC index with DDDs "ATC/DDD Index 2021". (2021). Retrieved from https://www.whocc.no/atc_ddd_index/
15. Spetsializovane medychne internet-vydannia dlia likariv, provizoriv, farmatsevtiv, studentiv medychnykh i farmatsevtychnykh vuziv "Kompendium Online", (2021). Retrieved from https://compendium.com.ua (in Ukrainian)
16. Servis "Liki control" (2021). Retrieved from http://likicontrol.com.ua. [in Ukrainian]
17. Online database "DrugBank Online" (2021). Retrieved from https://www.drugbank.com
18. Online database "Drugs.com" (2021). Retrieved from https://www.drugs.com
19. Halterman, P., Vogelzang, N.J., Farabishahadel, A., & Goodman O.B. (2010). Mitoxantrone. In: Figg W., Chau C., Small E. (eds) Drug Management of Prostate Cancer. New York: Springer.
https://doi.org/10.1007/978-1-60327-829-4_11
20. Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E.,. Reginster, J. Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & aging, 33(2), 75-85. doi: 10.1007/s40266-016-0347-4
https://doi.org/10.1007/s40266-016-0347-4
21. Report on Carcinogens, Fourteenth Edition (2016, November 3). Danthron. Retrieved from https://ntp.niehs. nih.gov/ntp/roc/content/profiles/danthron.pdf
22. Lichtman M. A. (2013). A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells, Molecules and Diseases, 50(2), 119-130. doi:10.1016/j.bcmd.2012. 10.005
https://doi.org/10.1016/j.bcmd.2012.10.005
23. Manufacturing Issues Remain for Indevus' Valstar (2008, January 11). Retrieved from https://www.fdanews. com/articles/103010-manufacturing-issues-remain-for-indevus-valstar Diaz-Muñoz, G., Miranda, I. L., Sartori, S. K., de Rezende, D. C., & Diaz, M. A. N. (2018). Chapter 11 - Anthraquinones: An Overview. Studies in Natural Products Chemistry, 58, 313-338. doi:10.1016/B978-0-444-64056-7.00011-8
https://doi.org/10.1016/B978-0-444-64056-7.00011-8
24. Koval'ov, V. M., Pavlin, O. I., & Isakova, T. I. (2004). Farmakohnoziya z osnovamy biokhimiyi roslyn. Vyd-vo NFaU MTK-knyha, Kharkiv.
25. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). Baytach. Retrieved from https://mozdocs. kiev.ua/likiview.php?id=28047
26. Sait "Normatyvno-dyrektyvni dokumenty MOZ Ukrayiny" (2021). PYRALVEX Retrieved from https://mozdocs.kiev.ua/likiview.php?id=3333